Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Legend Biotech Corp LEGN

Healthcare Biotechnology
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LEGN)

CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma

Business Wire 1 day ago

Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results

Business Wire 13 days ago

Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma

Business Wire April 5, 2024

Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report

Business Wire March 19, 2024

CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Business Wire March 15, 2024

Legend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent Highlights

Business Wire March 11, 2024

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of Therapy

Business Wire February 23, 2024

Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 Results

Business Wire February 13, 2024

Legend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3

Business Wire January 3, 2024
View More News ››

Opinion & Analysis (NDAQ:LEGN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:LEGN)

Legend Biotech Announces Positive CHMP Opinion for CARVYKTI&

Just In: $LEGN Legend Biotech Announces Positive CHMP Opinion for CARVYKTI&#xAE; (ciltacabtagene autoleucel) for the Treatment of...
whytestocks - February 23, 2024
View more Bullboard ››

SEGO Resources Inc

SEGO Resources Inc

SEGO Resources Inc. is a Canada-based exploration stage company. The Company is engaged in the acquisition, exploration, and ...
View More »